

2026 World Conference on Lung Cancer

SEPTEMBER 12 – 15, 2026 | SEOUL, REPUBLIC OF KOREA


Targeting Homologous Recombination Repair to Enhance Neoadjuvant Chemo-Immunotherapy in NSCLC

Lu Han, Zhenxin Sheng, Rui Yao, Weirong Zhang, Hongyi Zhang, Yilv Yan,

Lele Zhang, Peng Zhang

Department of Thoracic Surgery, Shanghai pulmonary hospital,
Shanghai, China


Key Q: Neoadjuvant chemo+IO: dissecting immune heterogeneity in non-responders.



Bulk RNA-seq Analysis: MPR vs. Non-MPR

Exploring targets to sensitize Neoadjuvant Chemo-IO

Results. **FIGNL1**: A Candidate Resistance Driver in Neoadjuvant Chemo-IO



Under revision


Conclusion

- **FIGNL1** is overexpressed in tumors from non-responders to neoadjuvant Chemo+IO.
- **Therapeutic implication**
Targeting FIGNL1 restores sensitivity to neoadjuvant Chemo-IO.
- **Translational potential**

A novel predictive biomarker and therapeutic target for patient stratification and combination therapy.

- **Next question?**

Mechanism-How does FIGNL1 regulate tumor cells to suppress CD8⁺ T cells infiltration and activation?



Thank You.